Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Grass Pollen Allergy Vaccine Also Effective Against Hepatitis B

By Medical University of Vienna | September 16, 2016

A new type of vaccine against grass pollen allergies (BM32) might also offer an effective treatment for combating hepatitis B infection.

This is the finding of a study conducted at MedUni Vienna’s Institute for Pathophysiology and Allergy Research that has now been published in EBioMedicine, with a commentary from international experts.

The BM32 vaccine is based on an innovative recombinant peptide-carrier technology, which—compared with other immunotherapies for allergy sufferers—requires far fewer injections and has fewer side-effects. Recombinant peptide-carrier technology was developed at the Christian Doppler Laboratory for Allergy Research at MedUni Vienna, under the direction of Rudolf Valenta. BM32 was developed jointly with commercial partner Biomay AG.

In a Phase IIb study conducted as part of her dissertation at the Institute for Pathophysiology and Allergy Research at MedUni Vienna, Carolin Cornelius discovered that BM32 is also a highly promising treatment option for combating hepatitis B infections.

“We were able to show that, in people who had not previously been immunized with a conventional hepatitis B vaccine, vaccination with BM32 achieved an average inhibition of hepatitis B virus infection of 80 percent,” said Cornelius.

According to the MedUni Vienna researcher, this suggests that the concept of peptide-carrier fusion proteins might also be a potential approach for improving hepatitis B immunization.

Up to 10 percent of those vaccinated for hepatitis B conventionally do not have effective antibodies.

“Ongoing investigations should help to produce a comprehensive characterization of the HBV neutralization capability of BM32. Apart from having a preventive effect, there might be additional benefits for patients suffering from chronic hepatitis B infection,” said Cornelius.

Hepatitis B infection is still one of the most widespread health problems in the world. The virus is detectable in the blood of around 350 million people. However, around five to 10 percent of those who have been vaccinated using a conventional vaccine fail to build up an adequate antibody titer.

“One can only assume that these people are not protected against infection,” said Cornelius.

In total, five research clusters have been established at MedUni Vienna. In these clusters, MedUni Vienna is increasingly focusing on fundamental and clinical research. The research clusters include medical imaging, cancer research/oncology, cardiovascular medicine, medical neurosciences, and immunology. This paper falls within the remit of the Cluster for Immunology.

To read the full press release, click here.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50